Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib

Fig. 2

Computed tomography images of one of our study patients with metastatic bronchoalveolar carcinoma which harbored exon 19 deletion treated with afatinib as 2nd TKI therapy after failure to gefitinib and chemotherapy. a. Baseline images showing diffuse ground glass opacities representing tumor infiltrates in lower lobes of both lungs. b. CT images at 3 months after afatinib showing significant reduction of tumor infiltrates. c. CT images at 6 months after afatinib showing further response and tumor shrinkage to afatinib

Back to article page